EVENTS | VIEW CALENDAR
BioTime and XenneX form platform for stem and progenitor cells
ALAMEDA, Calif.—BioTime Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, and XenneX Inc., a biomedical research tool provider, recently announced the formation of LifeMap Sciences Inc., a joint effort that plans to make available a database for use by stem cell researchers.
"The opportunity to develop a platform for stem and progenitor cells is one we could not let pass," said Dr. David Warshawsky, chairman of the board of XenneX, in a statement. "The aging baby boom population and rising costs of healthcare make cost-effective therapies in age-related diseases a near-term necessity. Stem and progenitor cells lines are instrumental in helping researchers develop therapeutics for these diseases. We aim to give them one place to find all the information they need to determine which cells they need for their research and the cell-related information necessary to develop life-saving cures in the future."
The database will permit users to follow the development of human embryonic stem cell (hESC) lines to the purified progenitor cell lines created by BioTime using its proprietary ACTCellerate technology through paid subscriptions or on a fee-per-use basis.
ACTCellerate was invented as a means of generating more than 140 diverse human progenitor cell types from hESC or induced pluripotent stem cells (iPS) in a scalable and highly purified state. These diverse cell lines have applications in basic laboratory research and are being marketed for that purpose.
"XenneX currently commercializes GeneCards, a leading relational database for information on each of the thousands of genes in human DNA, a resource widely used by medical researchers," stated Dr. Michael D. West, president and CEO of BioTime. "In a similar manner, working with XenneX, we plan to accomplish the first detailed roadmap of the complexities of the thousands of cell types that arise from human embryonic stem cells. Just as GeneCards has benefitted the field of molecular biology, we believe the database created by LifeMap Sciences will benefit cell biologists, and will provide high visibility to our diverse portfolio of novel progenitor cell types currently marketed to the research community."